AGWCA
ALNY icon

Annis Gardner Whiting Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-72
Closed -$17.5K – 739
2024
Q2 		$17.5K Hold
72
– – 0.01% 592
2024
Q1 		$10.8K Buy
+72
New +$12K ﹤0.01% 656

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's ALNY Position: Q3 2024 in Review

Annis Gardner Whiting Capital Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 72 shares — an estimated $17.5K sold.

Annis Gardner Whiting Capital Advisors first reported a position in ALNY in Q1 2024 and held it in 2 quarters. The position peaked at $17.5K in Q2 2024. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

  • Annis Gardner Whiting Capital Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 72 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $17.5K.
  • Annis Gardner Whiting Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Annis Gardner Whiting Capital Advisors's Alnylam Pharmaceuticals position peaked at $17.5K in Q2 2024.
  • 567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.